Savithri Ramurthy

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors
    Savithri Ramurthy
    Global Discovery Chemistry Oncology and Exploratory Chemistry, Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA
    Bioorg Med Chem Lett 22:1678-81. 2012
  2. ncbi Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors
    Savithri Ramurthy
    Novartis Institutes for BioMedical Research, 4560 Horton Street, Emeryville, California 94608, USA
    J Med Chem 51:7049-52. 2008
  3. ncbi Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors
    Savithri Ramurthy
    Global Discovery Chemistry Oncology and Exploratory Chemistry, Novartis Institutes for BioMedical Research, 4560 Horton Street, Emeryville, CA 94608, USA
    Bioorg Med Chem Lett 21:3286-9. 2011
  4. ncbi 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors
    Zhi Jie Ni
    Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    Bioorg Med Chem Lett 16:3121-4. 2006

Detail Information

Publications4

  1. ncbi Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors
    Savithri Ramurthy
    Global Discovery Chemistry Oncology and Exploratory Chemistry, Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA
    Bioorg Med Chem Lett 22:1678-81. 2012
    ..Scaffolds were assessed for in vitro Braf(V600E) inhibition, and overall kinase selectivity. Pharmacokinetic parameters for one of the scaffolds were also determined...
  2. ncbi Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors
    Savithri Ramurthy
    Novartis Institutes for BioMedical Research, 4560 Horton Street, Emeryville, California 94608, USA
    J Med Chem 51:7049-52. 2008
    ..A series of arylaminobenzimidazoles was designed and synthesized as Raf kinase inhibitors. Exploration of the structure-activity relationship resulted in compounds that are potent in vitro and show desirable in vivo properties...
  3. ncbi Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors
    Savithri Ramurthy
    Global Discovery Chemistry Oncology and Exploratory Chemistry, Novartis Institutes for BioMedical Research, 4560 Horton Street, Emeryville, CA 94608, USA
    Bioorg Med Chem Lett 21:3286-9. 2011
    ..The scaffolds were assessed for in vitro pan-Raf inhibition, activity in cell proliferation and target modulation assays, and pharmacokinetic parameters...
  4. ncbi 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors
    Zhi Jie Ni
    Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
    Bioorg Med Chem Lett 16:3121-4. 2006
    ..These compounds are potent cell permeable CHK-1 inhibitors and showed synergistic effect with a DNA-damaging agent, camptothecin...